References
- Andersen M, Schønnemann KR, Yilmaz M, Jensen HA, Vestermark LW, Pfeiffer P. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta Oncol 2010 Apr 29. [Epub ahead of print]
- Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24: 4991–7.
- Le Tourneau C, Lee J, Siu L. Dose escalation methods in phase I cancer clinical trials. J Natl Can 2009;101: 708–20.
- Shah MA, Shibata S, Stoller RG, Kemeny M, Ritch PS, Krishnamurthi SS. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE) [abstract 4014]. J Clin Oncol 2010.